All Posts
Five for Friday – Five New Items in the CCF Store
Home / Blog / [wpbb post:title] CCF swag is a great and simple way to raise cholangiocarcinoma awareness. Whether it's…
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
Study Name A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With…
Five for Friday – Five Community Member Spotlights
Home / Blog / [wpbb post:title] Each month, we recognize those whose contributions inspire us and who demonstrate excellence with…
Five for Friday – Five Educational Webinars
Home / Blog / [wpbb post:title] Did you know that CCF records all of the Educational Webinars and uploads them…
Patient Perspectives in Cross-Over Arms in Clinical Oncology Trials
The Cholangiocarcinoma Foundation (CCF) has released a new white paper, "Cross-over arms in oncology clinical trials: An important consideration for…
Dr. Juan Valle Named Cholangiocarcinoma Foundation's First Chief Medical Officer
The Cholangiocarcinoma Foundation announced the appointment of Dr. Juan Valle as its first Chief Medical Officer. Dr. Valle brings a…
Scientific Update – Radiation-releasing “seeds” may slow cholangiocarcinoma growth by inhibiting VEGFR2 singling
External radiation has been used to treat cancer for many years, but recent technological advances have led to a new…
Five for Friday – Clinical trials are essential to the cholangiocarcinoma community
Home / Blog / [wpbb post:title] In many cases, they can save lives. Finding the right clinical trial for YOU…
Five for Friday – 5 Resources for support, coping with the fear of recurrence
Home / Blog / [wpbb post:title] For cancer survivors, fear of cancer coming back after treatment, often referred to as…
Five for Friday – Five ways to use Recite Me
Home / Blog / [wpbb post:title] Did you know the CCF website has language, translation and accessibility options available? Recite…